Alcobra Ltd. (Nasdaq: ADHD) reported disappointing results from a Phase 3 clinical trial of Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder in adult patients. Shares of the biopharmaceutical plummeted 96 cents to close at $0.94.
Alcobra trial results fall short
January 17, 2017 at 16:42 PM EST
